Assessing the direct costs of treating nonvalvular atrial fibrillation in the United States

被引:324
作者
Coyne, Karin S.
Paramore, Clark
Grandy, Susan
Mercader, Marco
Reynolds, Matthew
Zimetbaum, Peter
机构
[1] United BioSource Corp, Ctr Hlth Outcomes Res, Bethesda, MD 20814 USA
[2] AstraZeneca LP, Wilmington, DE USA
[3] George Washington Univ, Washington, DC USA
[4] Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Boston, MA USA
关键词
atrial fibrillation; cost; resource use; retrospective study;
D O I
10.1111/j.1524-4733.2006.00124.x
中图分类号
F [经济];
学科分类号
02 ;
摘要
Objective: To determine the health-care resource use and costs attributable to treating atrial fibrillation (AF) in the United States. Methods: Retrospective analyses of three federally funded US databases (2001 data): 1) hospital inpatient stays (the Healthcare Cost and Utilization Project [HCUP]); 2) physician office visits (the National Ambulatory Medical Care Survey [NAMCS]); and 3) emergency department (ED) and hospital outpatient department visits (OPD) (the National Hospital Ambulatory Medical Care Survey [NHAMCS]). Identification of AF medical encounters was based on occurrence of AF-specific International Classification of Diseases (9th Edition)-Clinical Modification (ICD-9-CM) diagnosis code 427.31 (principal discharge diagnosis for inpatient setting; any diagnosis field for other settings). For the 10 most common principal discharge diagnoses in the inpatient setting, case-control comparison analyses were performed to estimate annual incremental costs of AF as a comorbid discharge diagnosis for hospital stays. Regression models were used to assess the impact of AF on hospitalization costs. Costs were estimated in year 2005 US dollars. Results: Approximately 350,000 hospitalizations, 5.0 million office visits, 276,000 ED visits, and 234,000 OPD were attributable to AF annually within the United States. Total annual costs for treatment of AF were estimated at $6.65 billion, including $2.93 billion (44%) for hospitalizations with a principal discharge diagnosis of AF, $1.95 billion (29%) for the incremental inpatient cost of AF as a comorbid diagnosis, $1.53 billion (23%) for outpatient treatment of AF, and $235 million (4%) for prescription drugs. In all regressions, AF was a significant contributor to hospital cost. Conclusions: Treatment of AF represents a significant health-care burden with the costs of treating AF in the inpatient setting outweighing the costs of treating AF in the office, emergency room or hospital outpatient settings. Further research is needed to fully capture the costs of treating AF.
引用
收藏
页码:348 / 356
页数:9
相关论文
共 37 条
[1]  
*AHA, HEART D2S STR35 STAT
[2]  
Anderson Robert J, 2004, J Manag Care Pharm, V10, P159
[3]   Trends and outcomes in the hospitalization of older Americans for cardiac conduction disorders or arrhythmias, 1991-1998 [J].
Baine, WB ;
Yu, W ;
Weis, KA .
JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2001, 49 (06) :763-770
[4]   Cost-effectiveness of cardioversion and antiarrhythmic therapy in nonvalvular atrial fibrillation [J].
Catherwood, E ;
Fitzpatrick, WD ;
Greenberg, ML ;
Holzberger, PT ;
Malenka, DJ ;
Gerling, BR ;
Birkmeyer, JD .
ANNALS OF INTERNAL MEDICINE, 1999, 130 (08) :625-+
[5]  
*CTR MED MED SERV, FAC CLAIMS US DEV AM
[6]  
*CTR MED MED SERV, 2001, DAT HOSP COST CHARG
[7]   REDUCTION IN MEDICAL-CARE COST ASSOCIATED WITH RADIOFREQUENCY CATHETER ABLATION OF ACCESSORY PATHWAYS [J].
DEBUITLEIR, M ;
SOUSA, J ;
BOLLING, SF ;
ELATASSI, R ;
CALKINS, H ;
LANGBERG, JJ ;
KOU, WH ;
MORADY, F .
AMERICAN JOURNAL OF CARDIOLOGY, 1991, 68 (17) :1656-1661
[8]   Acute treatment of atrial fibrillation: Spontaneous conversion rates and cost of care [J].
Dell'Orfano, JT ;
Patel, H ;
Wolbrette, DL ;
Luck, JC ;
Naccarelli, GV .
AMERICAN JOURNAL OF CARDIOLOGY, 1999, 83 (05) :788-790
[10]   Making decisions about antithrombotic therapy in heart disease: Decision analytic and cost-effectiveness issues [J].
Eckman, MH ;
Levine, HJ ;
Salem, DN ;
Pauker, SG .
CHEST, 1998, 114 (05) :699S-714S